Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism.

  • Victoria Sherwood
  • Shivendra Chaurasiya
  • Elin Ekström
  • William Guilmain
  • Qing Liu
  • Tomas Koeck
  • Kate Brown
  • Karin M Hansson
  • Margrét Agnarsdóttir
  • Michael Bergqvist
  • Karin Jirström
  • Fredrik Ponten
  • Peter James
  • Tommy Andersson
Publishing year: 2014
Language: English
Pages: 784-794
Publication/Series: Carcinogenesis
Volume: 35
Issue: 4
Document type: Journal article
Publisher: Oxford University Press

Abstract english

WNT5A has been identified as an important ligand in the malignant progression of a number of tumours. Although WNT5A signalling is often altered in cancer, the ligand's role as either a tumour suppressor or oncogene varies between tumour types and is a contemporary issue for investigators of β-catenin-independent WNT signalling in oncology. Here, we report that one of the initial effects of active WNT5A signalling in malignant melanoma cells is an alteration in cellular energy metabolism and specifically an increase in aerobic glycolysis. This was found to be at least in part due to an increase in active Akt signalling and lactate dehydrogenase (LDH) activity. The clinical relevance of these findings was strengthened by a strong correlation (P < 0.001) between the expression of WNT5A and LDH isoform V in a cohort of melanocytic neoplasms. We also found effects of WNT5A on energy metabolism in breast cancer cells, but rather than promoting aerobic glycolysis as it does in melanoma, WNT5A signalling increased oxidative phosphorylation rates in breast cancer cells. These findings support a new role for WNT5A in the metabolic reprogramming of cancer cells that is a context- dependent event.


  • Cancer and Oncology


  • CREATE Health
  • Experimental Pathology, Malmö
  • ISSN: 0143-3334
Peter James
E-mail: peter [dot] james [at] immun [dot] lth [dot] se


Department of Immunotechnology

+46 46 222 14 96

+46 70 247 79 60